BOCCHIA, MONICA
 Distribuzione geografica
Continente #
NA - Nord America 17.586
EU - Europa 15.589
AS - Asia 3.318
SA - Sud America 582
AF - Africa 90
OC - Oceania 28
Continente sconosciuto - Info sul continente non disponibili 13
Totale 37.206
Nazione #
US - Stati Uniti d'America 17.508
GB - Regno Unito 4.196
IE - Irlanda 2.663
IT - Italia 2.410
CN - Cina 1.666
UA - Ucraina 1.383
RU - Federazione Russa 1.204
SE - Svezia 1.188
SG - Singapore 1.069
FR - Francia 820
DE - Germania 800
BR - Brasile 496
FI - Finlandia 476
VN - Vietnam 129
HK - Hong Kong 106
NL - Olanda 105
TR - Turchia 78
BE - Belgio 66
IN - India 58
CA - Canada 43
CZ - Repubblica Ceca 43
AT - Austria 42
JP - Giappone 34
AR - Argentina 31
CI - Costa d'Avorio 30
IR - Iran 27
PL - Polonia 27
ES - Italia 26
MX - Messico 25
AU - Australia 21
EE - Estonia 20
PK - Pakistan 19
EG - Egitto 18
LT - Lituania 17
MA - Marocco 17
EC - Ecuador 16
IQ - Iraq 14
PH - Filippine 13
CH - Svizzera 12
CL - Cile 11
KZ - Kazakistan 10
EU - Europa 9
GR - Grecia 9
PT - Portogallo 9
RO - Romania 9
AZ - Azerbaigian 8
DK - Danimarca 8
RS - Serbia 8
UZ - Uzbekistan 8
BD - Bangladesh 7
IL - Israele 7
LV - Lettonia 7
NZ - Nuova Zelanda 7
VE - Venezuela 7
ZA - Sudafrica 7
HR - Croazia 6
LK - Sri Lanka 6
LU - Lussemburgo 6
MY - Malesia 6
PE - Perù 6
SA - Arabia Saudita 6
SK - Slovacchia (Repubblica Slovacca) 6
TN - Tunisia 6
AE - Emirati Arabi Uniti 5
BG - Bulgaria 5
BO - Bolivia 5
DZ - Algeria 5
ID - Indonesia 5
LA - Repubblica Popolare Democratica del Laos 5
CO - Colombia 4
KG - Kirghizistan 4
TH - Thailandia 4
AM - Armenia 3
DO - Repubblica Dominicana 3
IM - Isola di Man 3
JO - Giordania 3
KE - Kenya 3
LB - Libano 3
NG - Nigeria 3
PY - Paraguay 3
UY - Uruguay 3
AL - Albania 2
BY - Bielorussia 2
CW - ???statistics.table.value.countryCode.CW??? 2
HN - Honduras 2
HU - Ungheria 2
JM - Giamaica 2
KR - Corea 2
PA - Panama 2
PS - Palestinian Territory 2
SM - San Marino 2
TW - Taiwan 2
A1 - Anonimo 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BN - Brunei Darussalam 1
GE - Georgia 1
IS - Islanda 1
KH - Cambogia 1
Totale 37.194
Città #
Southend 3.821
Dublin 2.648
Fairfield 2.487
Ashburn 1.518
Chandler 1.353
Houston 1.245
Woodbridge 1.239
Jacksonville 1.112
Santa Clara 1.094
Wilmington 1.001
Seattle 955
Cambridge 789
Ann Arbor 648
Siena 538
Princeton 523
Singapore 421
Nanjing 400
Beijing 323
Helsinki 236
Milan 214
Boardman 203
San Mateo 179
Florence 171
San Diego 133
Munich 132
Dearborn 125
Dong Ket 122
Nanchang 117
New York 115
Moscow 108
Rome 107
Hong Kong 94
Shanghai 89
Hebei 82
London 78
Shenyang 75
Tianjin 69
Los Angeles 62
The Dalles 60
Brussels 57
Kunming 56
Nuremberg 56
Düsseldorf 53
Menlo Park 53
Jiaxing 52
Izmir 50
Jinan 46
Council Bluffs 45
Turin 41
Changsha 40
Falls Church 40
Norwalk 40
Portsmouth 36
São Paulo 35
Lauterbourg 34
Brno 33
Washington 31
Abidjan 30
Frankfurt am Main 30
Lappeenranta 30
Hangzhou 27
San Francisco 27
Guangzhou 26
Ningbo 26
Bologna 23
Toronto 23
Zhengzhou 22
Fremont 21
Hefei 20
Kilburn 20
Tallinn 20
Lanzhou 19
Rio de Janeiro 19
Vienna 19
Amsterdam 17
Taizhou 17
Bari 16
Dallas 16
Changchun 15
Livorno 15
Naples 15
Padova 15
Belo Horizonte 14
Edinburgh 14
Tokyo 14
Haikou 13
Newark 13
North Bergen 13
Palermo 13
Redwood City 13
Stockholm 13
Chiswick 12
Málaga 12
Venezia 12
Verona 12
Atlanta 11
Hounslow 11
Leawood 11
Cairo 10
Hyderabad 10
Totale 26.233
Nome #
VEXAS syndrome: a new paradigm for adult-onset monogenic autoinflammatory diseases 662
null 398
Mycosis Fungoides: a therapeutical review 330
MACOP-B versus F-MACHOP regimen in the treatment of high grade Non-Hodgkin’s Lymphomas 306
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis 224
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib 223
Intravenous (IV) bortezomib infusion after non-response to subcutaneous bortezomib administration can induce transitory responses in multiple myeloma patients: Are some patients more sensitive to IV bortezomib? 219
Residual peripheral blood CD26+leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission 219
Decreased plasma endogenous soluble RAGE, and enhanced adipokine secretion, oxidative stress and platelet/coagulative activation identify non-alcoholic fatty liver disease among patients with familial combined hyperlipidemia and/or metabolic syndrome 214
Low-level TP53 mutational load antecedes clonal expansion in chronic lymphocytic leukaemia 212
Flow Cytometry Assessment of CD26+ Leukemic Stem Cells in Peripheral Blood: A Simple and Rapid New Diagnostic Tool for Chronic Myeloid Leukemia 208
Atherothrombotic Risk and TKIs Treatment In Chronic Myeloid Leukemia Patients: A Role For Genetic Predisposition and Pro-Inflammatory/Pro-Oxidative Status? 207
Second generation proteasome inhibitors in multiple myeloma 205
Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients 204
Antibody and B-cell responses in myelofibrosis patients after the third doses of mRNA SARS-CoV-2 vaccines 191
Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura 185
Human cytotoxic T lymphocytes form dysfunctional immune synapses with B cells characterized by non-polarized lytic granule release 185
New perspectives for patients with primary CNS lymphoma 181
Study of gene polymorphisms as predictors of treatment efficacy and toxicity in patients with indolent non-hodgkin lymphomas and mantle cell lymphoma receiving bendamustine and rituximab 181
Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients. 177
Additional chromosomal abnormalities in Philadelphia-positive clone: Adverse prognostic influence on frontline imatinib therapy: A GIMEMA Working Party on CML analysis 175
Central nervous system multiple myeloma 174
Unravelling the response of chronic lymphocytic leukemia to a novel class of anticancer agents, the pyrrolonaphthoxazepines (PNOXs) 174
The Polycomb BMI1 Protein Is Co-expressed With CD26+ in Leukemic Stem Cells of Chronic Myeloid Leukemia 172
Ectopic ILT3 controls BCR-dependent activation of Akt in B-cell chronic lymphocytic leukemia 169
Lenalidomide and temozolomide combination in a very elderly patient with CNS relapse of diffuse large B-cell lymphoma 169
Atherothrombotic risk assessment during tyrosine kinase inhibitors treatment in chronic myeloid leukemia patients: new insight? 168
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party 167
Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors 167
The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia 166
Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib 166
Variant Philadelphia translocations: Molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA working party on CML analysis 165
Pilot study of gemtuzumab ozogamicin (GO), fludarabine, cytarabine and idarubicin combined regimen (GO-FLAI) as first-line induction therapy plus GO alone as consolidation therapy for elderly acute myeloid leukemia patients. 165
Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. 163
Radiotherapy plus rituximab as first-line regimen for localized follicular lymphoma 163
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia 161
Prognostic significance of lymphocyte/monocyte count and neutrophil/lymphocyte count in peripheral T cell lymphoma 161
Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses 160
Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia 159
Emerging drugs in chronic myelogenous leukaemia 158
Durable response after VNCOP-B and rituximab in an elderly patient with high-grade B-cell lymphoma 157
Imatinib does not impair specific antitumor T-cell immunity in patients with chronic myeloid leukemia 157
Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients 157
Real-world experience with decitabine as a first-line treatment in 306 elderly acute myeloid leukaemia patients unfit for intensive chemotherapy 157
High CD200 expression is associated with poor prognosis in cytogenetically normal acute myeloid leukemia, even in FlT3-ITD-/NPM1+ patients 156
Evaluation of the prognostic role of tumour-associated macrophages in newly diagnosed classical Hodgkin lymphoma and correlation with early FDG-PET assessment 156
Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series 155
Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice 155
Long term remission in a case of Plasmablastic lymphoma treated with COMP (Cyclophosphamide, Liposomal Doxorubicin, Vincristine, Prednisone) and Bortezomib 153
Efficacy and safety of rituximab plus bendamustine for gastric marginal zone lymphoma 153
Therapeutic use of Brentuximab Vedotin In Cd30+ hematologic malignancies 152
Primary Nasopharyngeal Hodgkin Lymphoma 152
Evolving treatments in multiple myeloma patients with renal failure 151
Peptide vaccines for hematological malignancies: a missed promise? 150
Treatment of smoldering multiple myeloma 150
A central nervous system CD56 positive multiple myeloma patient with a t(11;14) (q11;q32): A case report 149
Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML working party analysis 149
Comparative genomic analysis of PML and RARA breakpoints in paired diagnosis/relapse samples of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy 149
Circulating CD34+/CD38-/CD26+ Leukemia Stem Cells along Chronic Myeloid Leukemia progression: differences between Chronic, Accelerated and Blast Phase 148
Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party 148
Chronic myeloid leukaemia with extreme thrombocytosis at presentation: Incidence, clinical findings and outcome 148
Prognostic role of m2 Tumour-Associated macrophages in lymphoproliferative disorders 148
Frontline Dasatinib Treatment in a “Real-Life” Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia 148
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients 148
Managing chronic myeloid leukemia for treatment-free remission: A proposal from the GIMEMA CML WP 148
Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases 148
Thrombotic thrombocytopenic purpura secondary to an occult adenocarcinoma 147
Long-term efficacy and toxicity of rituximab plus fludarabine and mitoxantrone (R-FM) for gastric marginal zone lymphoma: a single-center experience and literature review 146
Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy. 145
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: A study by the GIMEMA working party on chronic myeloid leukemia 144
Unusual localizations of plasmacytoma 144
Genetic predisposition and induced pro-inflammatory/pro-oxidative status may explain increased atherothrombotic risk during TKI treatment in chronic myeloid leukemia patients 143
Radiotherapy with rituximab as first-line treatment for early-stage follicular lymphoma 143
Hyperlipidemia in a myeloma patient after bortezomib treatment 142
A der(1)t(1;21)(p36.3;q22) in a patient with acute myelogenous leukemia M2 142
Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia 142
Single agent lenalidomide activity in multiple myeloma relapse evidenced uniquely by CT/PET 142
Treatment decisions and outcome in very elderly patients with diffuse large B-Cell lymphoma 142
Anaplastic large cell lymphoma (CD30+/Ki-1+): results of a prospective clinico-pathological study of 69 cases 141
Overview of Anti-SARS-CoV-2 Immune Response Six Months after BNT162b2 mRNA Vaccine 141
Identification of a Novel P190-Derived Breakpoint Peptide Suitable for Peptide Vaccine Therapeutic Approach in Ph+ Acute Lymphoblastic Leukemia Patients. 140
Alpha-2b recombinant interferon (Intron) in Hodgkins' lymphoma: Therapeutic perspective 139
Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, Philadelphia-positive chronic myeloid leukemia: The GIMEMA working party on CML 139
Extramedullary myeloma relapses 138
Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: A phase 2 trial of the GIMEMA CML Working Party 137
Differences among young adults, adults and elderly chronic myeloid leukemia patients 137
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial 137
Primary CNS lymphoma: latest updates and a 10-year monocenter experience 137
Very late relapse in a patient with chronic myeloid leukemia in sustained complete cytogenetic response under imatinib 137
Rituximab plus liposomal pegylated doxorubicin in the treatment of primary cutaneous B-cell lymphomas 137
Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline 137
The response to imatinib and interferon- is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. 136
FLT3 inhibitors in the management of acute myeloid leukemia 136
Prospective Phase II Study on 5-Days Azacitidine for Treatment of Symptomatic and/or Erythropoietin Unresponsive Patients with Low/INT-1–Risk Myelodysplastic Syndromes. 135
A case of i(11)(q10) as sole cytogenetic abnormality in a patient with acute lymphoblastic leukemia 134
The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: The GIMEMA CML Working Party experience after a 7-year follow-up 133
Efficacy and safety of rituximab plus low-dose oral fludarabine and cyclophosphamide as first-line treatment of elderly patients with indolent non-Hodgkin lymphomas 133
Central Nervous System Multiple Myeloma 132
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: Retrospective analysis of 530 patients 132
Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients 131
Totale 16.916
Categoria #
all - tutte 137.925
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 137.925


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020573 0 0 0 0 0 0 0 0 0 0 165 408
2020/20215.411 242 628 274 570 307 572 300 785 483 410 397 443
2021/20223.671 264 441 256 332 154 154 137 140 202 404 419 768
2022/20235.251 333 348 634 714 510 1.032 129 476 534 69 343 129
2023/20244.645 182 119 368 336 175 1.035 1.407 397 62 127 87 350
2024/20256.251 334 507 935 547 1.083 545 291 627 830 487 65 0
Totale 37.983